ROCKLAND, Mass.--(BUSINESS WIRE)--Feb. 23, 2006--BioSphere Medical, Inc. (NASDAQ: BSMD) a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a procedure called embolization today announced the completion of a previously announced private placement of 2,075,000 shares of common stock to selected accredited investors at a price of $7.00 per share, which resulted in net proceeds to Biosphere of approximately $13.4 million after the deduction of offering expenses. Roth Capital Partners, LLC acted as exclusive placement agent in connection with the transaction.
